HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Author | Patrick Campbell


Deucravacitinib Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis

Bristol Myers Squibb announced the US FDA has approved their first-in-class, oral, selective, allosteric TYK2 inhibitor, deucravacitinib (Sotkytu), for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

American Heart Association Issues Advisory on Oral Penicillin in Patients With High-Risk Rheumatic Heart Disease

The AHA released a statement related to use of oral penicillin for patients with high-risk rheumatic heart disease, including patients with severe mitral stenosis, aortic stenosis, left ventricular systolic dysfunction, or active symptoms of rheumatic heart disease.